Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of New Pazopanib Formulation in Advanced Cancer
NCT02810756Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pazopanib in cancer and metastatic cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Plasma concentration at 24 hours. Started Sep 2016; status: completed.
02
Drugs
pazopanib
03
Conditions
cancermetastatic cancer
Beyond the preview
Go deeper on NCT02810756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810756.